Solara Active Pharma Sciences Limited (SOLARA) Fair Value & Analysis
Healthcare · IN · Market cap ₹27.8B
Fair value as of: Jul 3, 2026
From 13 valuation models · updated today
Share price +6.9% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹425.55 – ₹697.00 · fair‑value band ₹94.15 – ₹253.99 · the ₹575.85 price screens above the ₹170.17 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Solara Active Pharma Sciences Limited (SOLARA) currently trades at ₹575.85, while our model-based Fair Value estimate is ₹170.17 — implying the stock looks roughly 70.4% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Solara Active Pharma Sciences Limited generated revenue of ₹13.7B at a net margin of -0.5%. Revenue grew 41.9% year over year. It earns a return on equity of -0.6%. Net debt stands at ₹6.4B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Solara Active Pharma Sciences Limited reported revenue of ₹13.7B in FY2026 versus ₹12.7B in FY2022, a compound +1.9%/yr. Reported net income was −₹74.1M in FY2026.
Is SOLARA fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Solara Active Pharma Sciences Limited (SOLARA) undervalued?
What is the fair value of SOLARA?
What is the quality score of SOLARA?
What is the revenue of Solara Active Pharma Sciences Limited (SOLARA)?
What is the net profit margin of SOLARA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.